Literature DB >> 24486587

Having pancreatic cancer with tumoral loss of ATM and normal TP53 protein expression is associated with a poorer prognosis.

Haeryoung Kim1, Burcu Saka, Spencer Knight, Michael Borges, Erica Childs, Alison Klein, Christopher Wolfgang, Joseph Herman, Volkan N Adsay, Ralph H Hruban, Michael Goggins.   

Abstract

PURPOSE: To determine how often loss of ataxia-telangiectasia-mutated (ATM) protein expression occurs in primary pancreatic ductal adenocarcinomas and to determine its prognostic significance. EXPERIMENTAL
DESIGN: The expression of ATM and TP53 was determined by immunohistochemistry in 397 surgically resected pancreatic ductal adenocarcinomas (Hopkins; Johns Hopkins Medical Institutions, Baltimore, MD), a second set of 159 cases (Emory; Emory University Hospital, Atlanta, GA), and 21 cancers after neoadjuvant chemoradiotherapy. Expression was correlated with the clinicopathologic parameters, including survival.
RESULTS: Tumoral ATM loss was observed in one cancer known to have biallelic inactivation of ATM and 50 of the first 396 (12.8%) cases, significantly more often in patients with a family history of pancreatic cancer (12/49; 24.5%) than in those without (38/347; 11.0%; P = 0.019). In the Hopkins series, ATM loss was associated with a significantly decreased overall survival in patients whose cancers had normal TP53 expression (P = 0.019) and was a significant independent predictor of decreased overall survival (P = 0.014). Seventeen (10.7%) of 159 Emory cases had tumoral ATM loss and tumoral ATM loss/normal TP53 was associated with poorer overall survival (P = 0.1). Multivariate analysis of the combined Hopkins/Emory cases found that tumoral ATM loss/normal TP53 was an independent predictor of decreased overall survival [HR = 2.61; confidence interval (CI), 1.27-5.37; P = 0.009]. Of 21 cancers examined after neoadjuvant chemoradiotherapy, one had tumoral loss of ATM; it had no histologic evidence of tumor response.
CONCLUSIONS: Tumoral loss of ATM protein was detected more often in patients with a family history of pancreatic cancer than in those without. Patients whose pancreatic cancers had loss of ATM but normal TP53 had worse overall survival after pancreatic resection. ©2014 AACR.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24486587      PMCID: PMC3975663          DOI: 10.1158/1078-0432.CCR-13-1239

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  34 in total

Review 1.  Familial pancreatic cancer--current knowledge.

Authors:  Detlef K Bartsch; Thomas M Gress; Peter Langer
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-06-05       Impact factor: 46.802

2.  The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma.

Authors:  M Tascilar; H G Skinner; C Rosty; T Sohn; R E Wilentz; G J Offerhaus; V Adsay; R A Abrams; J L Cameron; S E Kern; C J Yeo; R H Hruban; M Goggins
Journal:  Clin Cancer Res       Date:  2001-12       Impact factor: 12.531

3.  Frequent detection of pancreatic lesions in asymptomatic high-risk individuals.

Authors:  Marcia Irene Canto; Ralph H Hruban; Elliot K Fishman; Ihab R Kamel; Richard Schulick; Zhe Zhang; Mark Topazian; Naoki Takahashi; Joel Fletcher; Gloria Petersen; Alison P Klein; Jennifer Axilbund; Constance Griffin; Sapna Syngal; John R Saltzman; Koenraad J Mortele; Jeffrey Lee; Eric Tamm; Raghunandan Vikram; Priya Bhosale; Daniel Margolis; James Farrell; Michael Goggins
Journal:  Gastroenterology       Date:  2012-01-12       Impact factor: 22.682

Review 4.  Assessing treatment effect in pancreatic cancer.

Authors:  Douglas J Hartman; Alyssa M Krasinskas
Journal:  Arch Pathol Lab Med       Date:  2012-01       Impact factor: 5.534

5.  Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis.

Authors:  Anna Yemelyanova; Russell Vang; Malti Kshirsagar; Dan Lu; Morgan A Marks; Ie Ming Shih; Robert J Kurman
Journal:  Mod Pathol       Date:  2011-05-06       Impact factor: 7.842

Review 6.  Identifying people at a high risk of developing pancreatic cancer.

Authors:  Alison P Klein
Journal:  Nat Rev Cancer       Date:  2012-12-06       Impact factor: 60.716

7.  Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes.

Authors:  Andrew V Biankin; Nicola Waddell; Karin S Kassahn; Marie-Claude Gingras; Lakshmi B Muthuswamy; Amber L Johns; David K Miller; Peter J Wilson; Ann-Marie Patch; Jianmin Wu; David K Chang; Mark J Cowley; Brooke B Gardiner; Sarah Song; Ivon Harliwong; Senel Idrisoglu; Craig Nourse; Ehsan Nourbakhsh; Suzanne Manning; Shivangi Wani; Milena Gongora; Marina Pajic; Christopher J Scarlett; Anthony J Gill; Andreia V Pinho; Ilse Rooman; Matthew Anderson; Oliver Holmes; Conrad Leonard; Darrin Taylor; Scott Wood; Qinying Xu; Katia Nones; J Lynn Fink; Angelika Christ; Tim Bruxner; Nicole Cloonan; Gabriel Kolle; Felicity Newell; Mark Pinese; R Scott Mead; Jeremy L Humphris; Warren Kaplan; Marc D Jones; Emily K Colvin; Adnan M Nagrial; Emily S Humphrey; Angela Chou; Venessa T Chin; Lorraine A Chantrill; Amanda Mawson; Jaswinder S Samra; James G Kench; Jessica A Lovell; Roger J Daly; Neil D Merrett; Christopher Toon; Krishna Epari; Nam Q Nguyen; Andrew Barbour; Nikolajs Zeps; Nipun Kakkar; Fengmei Zhao; Yuan Qing Wu; Min Wang; Donna M Muzny; William E Fisher; F Charles Brunicardi; Sally E Hodges; Jeffrey G Reid; Jennifer Drummond; Kyle Chang; Yi Han; Lora R Lewis; Huyen Dinh; Christian J Buhay; Timothy Beck; Lee Timms; Michelle Sam; Kimberly Begley; Andrew Brown; Deepa Pai; Ami Panchal; Nicholas Buchner; Richard De Borja; Robert E Denroche; Christina K Yung; Stefano Serra; Nicole Onetto; Debabrata Mukhopadhyay; Ming-Sound Tsao; Patricia A Shaw; Gloria M Petersen; Steven Gallinger; Ralph H Hruban; Anirban Maitra; Christine A Iacobuzio-Donahue; Richard D Schulick; Christopher L Wolfgang; Richard A Morgan; Rita T Lawlor; Paola Capelli; Vincenzo Corbo; Maria Scardoni; Giampaolo Tortora; Margaret A Tempero; Karen M Mann; Nancy A Jenkins; Pedro A Perez-Mancera; David J Adams; David A Largaespada; Lodewyk F A Wessels; Alistair G Rust; Lincoln D Stein; David A Tuveson; Neal G Copeland; Elizabeth A Musgrove; Aldo Scarpa; James R Eshleman; Thomas J Hudson; Robert L Sutherland; David A Wheeler; John V Pearson; John D McPherson; Richard A Gibbs; Sean M Grimmond
Journal:  Nature       Date:  2012-10-24       Impact factor: 49.962

8.  The mTOR pathway negatively controls ATM by up-regulating miRNAs.

Authors:  Changxian Shen; Peter J Houghton
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-01       Impact factor: 11.205

9.  ATM mutations in patients with hereditary pancreatic cancer.

Authors:  Nicholas J Roberts; Yuchen Jiao; Jun Yu; Levy Kopelovich; Gloria M Petersen; Melissa L Bondy; Steven Gallinger; Ann G Schwartz; Sapna Syngal; Michele L Cote; Jennifer Axilbund; Richard Schulick; Syed Z Ali; James R Eshleman; Victor E Velculescu; Michael Goggins; Bert Vogelstein; Nickolas Papadopoulos; Ralph H Hruban; Kenneth W Kinzler; Alison P Klein
Journal:  Cancer Discov       Date:  2011-12-29       Impact factor: 39.397

10.  International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer.

Authors:  Marcia Irene Canto; Femme Harinck; Ralph H Hruban; George Johan Offerhaus; Jan-Werner Poley; Ihab Kamel; Yung Nio; Richard S Schulick; Claudio Bassi; Irma Kluijt; Michael J Levy; Amitabh Chak; Paul Fockens; Michael Goggins; Marco Bruno
Journal:  Gut       Date:  2012-11-07       Impact factor: 23.059

View more
  30 in total

1.  Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma.

Authors:  Brian A Boone; Nathan Bahary; Amer H Zureikat; A James Moser; Daniel P Normolle; Wen-Chi Wu; Aatur D Singhi; Phillip Bao; David L Bartlett; Lance A Liotta; Virginia Espina; Patricia Loughran; Michael T Lotze; Herbert J Zeh
Journal:  Ann Surg Oncol       Date:  2015-04-24       Impact factor: 5.344

Review 2.  Individualized radiotherapy (iRT) concepts for locally advanced pancreatic cancer (LAPC): indications and prognostic factors.

Authors:  Stephanie E Combs
Journal:  Langenbecks Arch Surg       Date:  2015-07-03       Impact factor: 3.445

3.  ATM Expression as a Prognostic Marker in Patients With Advanced Biliary Tract Cancer Treated With First-line Gemcitabine and Platinum Chemotherapy.

Authors:  Hyera Kim; Seung Tae Kim; Kwai Han Yoo; Jung Yong Hong; Young Suk Park; Ho Yeong Lim; Joon Oh Park
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

Review 4.  Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?

Authors:  Min Yuen Teo; Eileen M O'Reilly
Journal:  J Gastrointest Oncol       Date:  2016-10

5.  CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis.

Authors:  Yue Wang; Bo Dai; Dingwei Ye
Journal:  Int J Clin Exp Med       Date:  2015-09-15

6.  Germline variants in pancreatic cancer patients with a personal or family history of cancer fulfilling the revised Bethesda guidelines.

Authors:  Akihiro Ohmoto; Chigusa Morizane; Emi Kubo; Erina Takai; Hiroko Hosoi; Yasunari Sakamoto; Shunsuke Kondo; Hideki Ueno; Kazuaki Shimada; Shinichi Yachida; Takuji Okusaka
Journal:  J Gastroenterol       Date:  2018-04-17       Impact factor: 7.527

7.  Germline Variants and Risk for Pancreatic Cancer: A Systematic Review and Emerging Concepts.

Authors:  Wei Zhan; Celeste A Shelton; Phil J Greer; Randall E Brand; David C Whitcomb
Journal:  Pancreas       Date:  2018-09       Impact factor: 3.327

8.  Prognostic relevance of ATM protein in uveal melanoma and its association with clinicopathological factors.

Authors:  Jayanti Jha; Mithalesh Kumar Singh; Lata Singh; Neelam Pushker; Mandeep Singh Bajaj; Seema Sen; Seema Kashyap
Journal:  Int J Clin Oncol       Date:  2019-08-03       Impact factor: 3.402

9.  Impact of p53 and PDGFR-β Expression on Metastasis and Prognosis of Patients with Pancreatic Cancer.

Authors:  Hiroshi Kurahara; Kosei Maemura; Yuko Mataki; Masahiko Sakoda; Hiroyuki Shinchi; Shoji Natsugoe
Journal:  World J Surg       Date:  2016-08       Impact factor: 3.352

Review 10.  DNA damage and the balance between survival and death in cancer biology.

Authors:  Wynand P Roos; Adam D Thomas; Bernd Kaina
Journal:  Nat Rev Cancer       Date:  2015-12-18       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.